Get the Stockscreener App
3.86
2.81%
-0.1117
After Hours:
3.86
Aprea Therapeutics Inc stock is traded at $3.86, with a volume of 9,169.
It is down -2.81% in the last 24 hours and up +48.46% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$3.9717
Open:
$4.0797
24h Volume:
9,169
Relative Volume:
0.42
Market Cap:
$21.57M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.698
EPS:
-5.53
Net Cash Flow:
$-12.27M
1W Performance:
-9.18%
1M Performance:
+48.46%
6M Performance:
-27.85%
1Y Performance:
-3.50%
1-Day Range:
$3.85
$4.0797
1-Week Range:
$3.82
$4.42
52-Week Range:
$2.1501
$8.8465
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
617-463-9385
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN
DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR
Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews
Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa
Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World
Aprea therapeutics director sells shares worth $29,583 - Investing.com India
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com
Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK
Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha
Aprea reports safe trial results for new cancer drug - Investing.com
Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News
Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St
Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India
Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com
Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa
Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia
Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo
Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India
Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada
Director Bernd Seizinger Acquires 10,000 Shares of Aprea Therape - GuruFocus.com
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit - ForexTV.com
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo
Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc - Yahoo Finance
Stonepine Capital Management, LLC Increases Stake in Aprea Thera - GuruFocus.com
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - ForexTV.com
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and - EIN News
Aprea Therapeutics Welcomes Dr. Philippe Pultar as Senior Medical Advisor - MyChesCo
Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo
APRE stock touches 52-week low at $2.22 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.22 amid market challenges - Investing.com UK
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development - The Manila Times
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MSN
Halda appoints new chief executive - The Pharma Letter
Stonepine Capital Management LLC Acquires Shares of 137,174 Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Halda Therapeutics Appoints Christian Schade as CEO - citybiz
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):